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Summary 
We have previously found that  a Tyr residue was critical for the interaction  of peptides with 
the  K d molecule,  and therefore may be acting as an anchor  residue.  In  the present  report we 
show that  it is possible to convert a sdf peptide sequence into a Kd-restricted neo-antigen by 
a single Tyr substitution at position 2 of the peptide. This supports the idea that Tyr is a critical 
element in  the binding  motif of Kd-restricted peptides and is a finding  that  could also prove 
useful for vaccine development. 
T 
lymphocytes recognize antigen in the form of peptides 
bound to MHC class I or class II molecules (reviewed 
in references 1 and 2). x-ray crystaUographic analysis  of the 
class I molecules HLA-A2 and HLA-Aw68 (3-5) showed a 
cleft on the MHC molecule that was proposed to be the pep- 
tide binding  site.  By using a functional competition  assay 
we have recently tried to define common structural features 
of peptides  recognized  in  the  context  of the  H-2K  a (K  a) 
MHC class I molecule (6). For the antigenic peptide HLA- 
A24 170-182,  it was initially shown that three residues (Tyr 
171, Thr  178,  and Leu 179) were important  in the interac- 
tion with K d. Subsequently, an analogue (AYPsTLA) con- 
taining these residues was demonstrated to be an efficient com- 
petitor for K d binding. A predominant influence on binding 
was found for the Tyr residue and we have demonstrated that 
four different Kd-restricted peptides all contain  a common 
Tyr residue that appears to be critical for competitor activity 
(6,  7). 
We  reasoned  that  if Tyr  was  a  critical  residue  for  K a 
binding, it should be possible to introduce a Tyr residue into 
a protein sequence and create a neo-epitope restricted by K d. 
To test this, we took advantage of the well characterized an- 
tigenic mutant  system developed by Boon et al.  (reviewed 
in reference 8). They have shown that  a high frequency of 
mutagenized P815 tumor cells express neo-antigens that can 
be recognized by CTL. The mutants are rejected by syngeneic 
mice,  and  hence  they  have  been  named  turn-  ("tumor- 
minus")  mutants.  For  three  different  turn-  mutants,  the 
genes encoding  the neo-antigens  have been cloned and se- 
quenced. The three genes, which are unrelated to each other 
and whose functions are as yet unknown, each contain a single 
point mutant that leads to the creation of a neo-epitope (8). 
One example is turn-  antigen  P91A-,  in which the point 
mutation resulted in a single amino acid change that created 
an La-restricted  CTL epitope (9). 
To initiate  the present  study,  we synthesized a series  of 
six overlapping ll-mer peptides whose sequences correspond 
to the wild-type (i.e.,  self) P91A +(tum +) sequence, except 
for the replacement of a single residue in each peptide with 
Tyr. The Tyr residue was introduced at the second position 
from the NH2 terminus in each peptide, since this position 
was found to be optimal for the four different Ka-restricted 
epitopes that we have analyzed previously (10). After testing 
these six peptides in a competition assay, we selected one that 
appeared to be optimal for K a binding and immunized mice 
of the H-2  d MHC haplotype. From these mice we could iso- 
late CTL specific for the immunizing peptide, and as predicted, 
all of the CTL clones thus obtained were H-2K  a restricted. 
Materials and Methods 
Cells.  The isolation and characterization of Kd-restricted CTL 
clone CS.H2 (P. Romero et al., manuscript  in preparation)  and 
of Ld-restricted CTL clone P91.6 (11) is described elsewhere. The 
CTL lines and clones specific for the peptide P91A 12-22/Y13 were 
isolated  from  BALB/c  or  (BALB/c  x  C57BL/6)F1  mice  im- 
munized with the peptide in Freund's adjuvant, as described else- 
where (P. Romero et al., manuscript  in preparation). 
Peptides.  Peptides were synthesized and purified as described 
elsewhere (6), and amino acid composition was confirmed by amino 
acid analysis. 
Cytolytic Assay.  Experiments  to assess peptide recognition  or 
competition  were performed as described elsewhere (6) in a 4-h 
51Cr release assay. The  percent  specific lysis was calculated as: 
100x  [(experimental -  spontaneous release)/(total -  spontaneous 
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Peptide  Sequence 
P91A +. 12-24 
P91A-. 12-24 
11-21/Y12 
12-22/Y13 
13-23/Y14 
14-24/Yls 
15-25/Y1~ 
16-26/Y17 
ISTQNRRALDLVA 
I  STQNHRALDLVA 
KYSTQNRRALD 
IYTQNRRALDL 
SYQNRRALDLV 
TYNRRALDLVA 
QYRRALDLVAA 
NYRALDLVAAK 
release)].  The percent control lysis was calculated as: 100x  [(per- 
cent specific lysis with competitor  -  background lysis)/(percent 
specific  lysis without  competitor  -  background lysis)].  Clone 
444/A1.1 (12) was used for P815 (H-2  d) target ceils.  The deriva- 
tion of L cell (H-2  k) transfectants that express H-2K  a and/or the 
mouse inter-cellular adhesion molecule 1 (ICAM-1) is described 
elsewhere (C. Jaulin et al., manuscript in preparation). 
Results and Discussion 
The Interaction of Tyr-substituted P91A §  Peptides with H-2K  J 
and H-2L(  The peptides shown in Table 1 were tested for 
their capacity to interact with K a and L d molecules by using 
a functional competition assay. The most active competitor 
for K d binding was the peptide 12-22/Y13,  which was as ac- 
tive as the peptide analogue AYPsTLA previously described 
(6) (Fig.  1). Peptides Y12, Y14, Y15, and Y16 also completed 
but  were  10-100-fold less  active,  whereas Yt7  was a poor 
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Figure  1.  Comparison  of  Tyr- 
substituted  P91A  +  Peptides as com- 
petitors  for  K  d- or Ld-restricted pep- 
tides,  slCr-labeled  P815 target  cells 
were  incubated  with  the  indicated 
concentrations  (final)  of  Peptides 
P91A+.12-24  (O--O),  AYPsTLA 
([]--V]), or MCMV pp89  168-176 
(" -- liB), or with the Tyr-substituted 
P91A §  Peptides  (see Table  1)  Y12 
(A--A), Y13 (A'-A), YI4 (A--A), 
Y1s (A---A), Y16 (V--V),  or Y17 
(V---V)  as  competitors.  Antigenic 
Peptides PbCS  252-260 and P91A-. 
12-24  were  added  at  final  con- 
centrations  of  10 -10  and  10 -s  M, 
respectively, and  cells from  the  K  d- 
restricted CTL done CTL-CS.H2 or the 
Ld-restricted CTL  done  CTbP91.6, 
respectively, were added at a 3:1 CTL 
to  target  ratio  in a 4-h 51Cr release 
assay. Lysis in the absence of compet- 
itor Peptides was 67%  and 63%  for 
CTbCS.H2  and  CTbP91.6,  respec- 
tively, and lysis  in the absence of pep- 
tides was <7%. The competitor  pep- 
tides were not recognized by either of 
the test CTL clones (not shown). 
80 
O~ 
60 
;>- 
.J 
O 
~-40 
O 
I1/ 
D,. 
u;,  20 
o~ 
.//.i. 
/ 
-9  -8  -7  -6  -5  / 
-9  -8  -7  -6  -5 
C 
PEPTIDE CONCENTRATION ( log,,, M ) 
-8  -7  -6  -5 
Figure 2.  CTL specific for the P91A Yt3 mutant pep- 
tide. SlCr-labeled P815 target cells were added to micro- 
titer plate wells at the indicated (final) concentrations of 
peptide. Effector cells were added at a 1:1 E/T cell ratio, 
and the assay was terminated after a 4-h incubation. (A) 
CTL line F1-1 effector cells were tested with the P91A 
YI3 mutant peptide (Q), the P91A  + peptide (12-24, ,), 
or the P91.A- peptide (12-24, []). The FI-1 CTL line was 
derived from  the spleen of a (BALB/c  x  C57BI/6)F1 
mouse immunized Sc with the Y13 peptide in IFA. The 
line was restimulated weekly with irradiated  BALB/c spleen 
cells and P815 cells pre-pulsed with the YI3 Peptide. (B) 
CTL clones 1.1 (Q), 1.5 (A), and 1.6 (V) were assayed 
on P815 targets  incubated with the P91A Y13 Peptide 
(closed symbo/s), the P91A + peptide (open symbols, solid line), or the P91A- Peptide (open symbols, broken line). The CTL clones were isolated from 
line F1-1 by limiting dilution after the fourth in vitro stimulation. They express V~13, V014, or V810, respectively,  and are thus dearly different clones. 
TCR expression was determined by flow cytometric analysis (not shown) using mAbs specific for Va13 (VB-TCR-6B; PharMingen,  San Diego, CA) 
or V~14 (14.2; reference 15) and/or by PCR (J.-U Casanova, personal communication). (C) Control CTL clone P91.6 (11) was assayed with the P91A 
Yt3 peptide (I), the P91A + peptide (I), and the P91A- Peptide (D). 
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were also tested as competitors for L  a binding.  Most of the 
peptides  were relatively  inefficient competitors in  the L d 
system compared with the La-restricted reference peptide 
MCMV pp89 168-176 (13) (Fig. 1). Moreover, the best com- 
petitor in the L  d system, peptide YtT, was the least effective 
competitor in  the K d system,  and inversely, peptide  Yt3, 
which was the most effident in the K d system, did not com- 
pete at aU in the L  d system. 
(BALB,/c  x  C57BI/6)FI  and BALB/c  Mice  Give  a  K d- 
restricted CTL Response when Immunized with Peptide PglA * 
Y13.  Since  the Yt3 peptide was the optimal K d binder and 
the weakest L d binder, it was selected as an immunogen. A 
CTL line (Ft-1) obtained from the spleen of a (BALB/c  x 
C57B1/6)F1 mouse immunized with the Y13  peptide  was 
highly active and specific for the immunizing peptide (Fig. 
2 A). 11 CTL clones were isolated from the Ft-1 line by lim- 
iting dilution and all were found to be specific for the Yt3 
peptide. As shown in Fig. 2 B, three of the CTL clones that 
express different TCR V3 chains (and can thus be consid- 
ered different clones) recognize the Y13 peptide but not pep- 
tides corresponding to  the P91A  + (self) sequence, or the 
P91A- (turn-) sequence. The latter peptide is recognized by 
the Ld-restricted CTL clone P91.6 (reference 9 and Fig. 2 C). 
As expected, this control CTL done did not recognize pep- 
tide Y13 (Fig. 2 C). 
All of the CTL clones were shown to be K d restricted. 
The results obtained with two independent clones are shown 
in Fig. 3.  The Kd-ICAM-1 double-transfectant  target  cells 
were specifically lysed in the presence of the Yt3 peptide, 
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Figure 3.  CTL clones specific for the P91A Y13 peptide  are Kd re- 
stricted. 51Cr-labeled  bKd-ICAM-1 (A, V) or L-ICAM-1 (A, ~7) target 
cells were added to wells of microtiter plates containing  the indicated con- 
centrations  (final) of peptide Y13. CTL from clone 1.5 (A, A) and 1.6 
(V, x7) were added at a 3:1 CTL to target ratio in a 4-h stCr-release assay. 
whereas control Ka-negative transfectant  target cells were 
not. We had found previously that the expression of ICAM-1 
on L cells improved levels oflysis (C. Jaulin andJ. Maryanski, 
data not shown). 
We have extended these findings by showing that Yt3- 
specific Kd-restricted  CTL  could  be  obtained  from  the 
spleens of three additional (BALB/c x  C57B1/6)Ft mice, as 
well as from two BALB/c mice (Fig. 4). 
We have recently defined a simple K d binding motif for 
synthetic  peptides  corresponding  to  four  different  K  d- 
restricted antigens (10). The motif is characterized by a Tyr 
residue in the second position from the NH2 terminus, and 
a hydrophobic residue of Leu, lie, or Val at position 9 or 10. 
The optimal peptide  from this study (Y13)  contains a Leu 
residue at position 9 and thus incorporates the complete K d 
motif that includes the Tyr residue introduced at position 
2 (Table 1). 
Using chromatographic techniques, Falk et al. (14) have 
recently identified putative binding motifs in peptides iso- 
lated from several different MHC class I molecules. Consis- 
tent with our results defining a K  a binding motif, they have 
shown that naturally occurring peptides bound to K  d appear 
to be predominantly 9-mers that have a Tyr at position 2 and 
a COOH-terminal Leu or lie residue. Our present study pro- 
vides further confirmation of the validity of the K d binding 
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Figure 4.  Both BALB/c and (C57B1/6  x  BALB/c)F1 mouse strains 
generate Ka-restricted CTL specific for  the P91A Y13 mutant peptide. 
SICr-hbeled bKa-ICAM-1 target cells at 2  x  104/ml, were incubated for 
15 min with 1/~M of peptide Y13. Cells from CTL lines derived from 
peptide-immunized  mice  of either  (BALB/c  (B-1 [0--0]  and  B-2 
[m---Ill) or BALB/c  x  C57BI/6)Ft  (F1-4 [0--0],  F1-5 [A--A], 
and Ft-7 [5'--V])  strains were added at the indicated lymphocyte to 
target ratios in a 4-h slCr release assay. The results shown were obtained 
4 d after the third in vitro restimulation.  Lysis in the absence of peptide 
is indicated by the open symbols. Only marginal lysis was observed on 
L-ICAM-1 targets in the presence of peptide Y13 (not shown). 
1659  Healy et al.  Brief Definitive Report motif and also suggests that it may be feasible to predict an- 
tigenic epitopes using structural motifs, a finding that could 
prove useful for vaccine development. Finally, the possibility 
of designing MHC-directed neo-antigens from self sequences 
(like P91A +) may be helpful for studies on self tolerance and 
the TCR repertoire. 
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Note Added in Proof: As would be predicted from our recent analysis  of other Kd-restricted  antigenic pep- 
tides (10), we have now found that CTL clones that recognize the 11-mer Y13 peptide also recognize 
the truncated nonamer sequence IYTQNRRAL, which contains the Leu anchor of the K  ~  binding motif 
at the COOH-terminus. 
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